B-cell prolymphocytic leukemia has 3 subsets

Abstract

In this issue of Blood, Chapiro et al1 have conducted a comprehensive genetic, clinical, and drug sensitivity analysis of a large series of B-prolymphocytic leukemia (B-PLL) cases and illustrated important new findings with implications for predicting clinical outcome.